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ABSTRACT: Vascular adhesion protein-1 (VAP-l) belongs to 
a family o f amine oxidases. It plays a role in leukocyte trafficking 
and in amine compound metabolism. VAP-l is linked to various 
diseases, such as Alzheimer’s disease, psoriasis, depression, 
diabetes, and obesity. Accordingly, selective inhibitors of 
VAP-l could potentially be used to treat those diseases. In this 
study, eight novel VAP-l hydrazine derivatives were synthesized 
and their VAP-l and monoamine oxidase (MAO) inhibition ability was determined in vitro. MD simulations of VAP-l with these 
new molecules reveal that the VAP-l ligand-binding pocket is flexible and capable o f fitting substantially larger ligands than was 
previously believed. The increase in the size o f the VAP-1 ligands, together with the methylation o f the secondary nitrogen atom of 
the hydrazine moiety, improves the VAP-l selectivity over MAO.
A mine oxidases (AOs) are enzymes that metabolize diverse 
-t lam in e  compounds by converting them into corresponding 
aldehydes with concomitant hydrogen peroxide and ammonia 
production. AOs can be divided into two families based on their 
cofactors. The first family of AOs includes monoamine oxidases 
A and B (MAOs A and B, EC 1.4.3.4.) and polyamine oxidase 
(EC 1.5.3.11.), which have flavin adenosine dinucleotide as a 
cofactor. The second family of AOs include diamine oxidase 
(DAO, EC 1.4.3.22.), lysyl oxidase (EC 1.4.3.13.), and vascular 
adhesion protein-1 (VAP-l, EC 1.4.3.21.), which all have mod­
ified tyrosine (topaquinone, TPQ) or lysine residue as a cofactor.
VAP-l is an interesting member o f the AO family. In addition 
to being an enzyme, it also has an adhesive task in leukocyte 
extravasation.1 VAP-l is a type II transmembrane glycoprotein 
with a large glycosylated extracellular domain and a short 
N-terminal intracellular domain, which is involved in the adhe­
sion o f lymphocytes to endothelial cells and lymphocyte recircu­
lation.1 VAP-l is primarily expressed on endothelial cells, but 
some expression is also detected in nonendothelial cells, e.g., 
blood vessel smooth muscle cells.2 VAP-l activity can exert 
insulin-like effects on glucose metabolism via hydrogen 
peroxide.3 Hydrogen peroxide acts as a local signaling molecule, 
but excess amounts can cause oxidative stress. Other reaction 
products are potential toxins as well; for example, methylglyoxal 
can form advanced glycation end products.4 Maintenance of 
constant levels o f the reaction products is crucial because in 
normal concentrations, they are beneficial and necessary, but 
increased or decreased amounts can cause severe diseases.
Alterations in reaction product levels and corresponding diseases
can arise from either overexpression5 11 or underexpression of VAP-
112-16 or from increased enzymatic activities of VAP-l.17-22
VAP-l is a potential target for drug development because it is 
involved in many diseases. Various VAP-l inhibitors have already 
been developed, such as phenylallylhydrazines23 thiocarbamoyl 
derivatives,24 carboxamides and sulfonamides,25 and hydrazines1, 
(Figure l). VAP-l function can also be modulated by using ( l )  
peptides with NH3+  functionality (lysine side chain),27-29 (2) func­
tion blocking antibodies (to inhibit the leukocyte trafficking),30 
and (3) small interfering RNAs (to inhibit both adhesion and 
enzymatic functions).31 Because amine oxidases have partly 
overlapping substrate specificities, it is challenging to design 
selective inhibitors for one member of an AO family. The 
compounds mentioned above establish a promising starting 
point for VAP-l blocking pharmaceuticals, but they are not 
selective or safe enough yet
The crystal structures determined for human VAP-l32-34 
show that the structure o f VAP-l is homodimeric. The active 
site is located near the dimerization interface, buried deep within 
the protein, and includes the TPQ_cofactor and the catalytic base 
(Asp386).32 34 The accessibility o f the active site is restricted by 
Leu469, which blocks the entrance to the ligand-binding site.3
We have recently reported that hydrazine derivatives are 
potential selective VAP-l inhibitors.26 The reaction mechanism
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b R= -C2H3 b R= 4-CI, R '=  H
c R= -CH2CH=CH2
Phenyialiyihydrazme a-d Pyrrollne
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d R= 2-CHj
Figure 1. Structures o f  some known small molecule VAP-1 inhibitors: phenylallylhydrazines,23 thiocarbamoyl derivatives,24 carboxamides and 
sulfonamides,25 hydrazines,1’26 and pyrroline derivatives.63
Figure 2. Binding of2-hydrazinopyridine (2-HP) to TPQ : (A) reaction mechanism o f VAP-1;36 (B) resonance structures o f 2-HP—TPQcomplex, the 
prevalent hydrazone form in physiological pH  and the distinctive azo form, detected at pH  > 9; (C ) 3D crystal structure o f bound 2-HP in human VAP-1 
(PDB code 2C1133); (D ) 3D crystal structure o f 2-HP in R  colt amine oxidase (PDB code 1SPU35).
of the TPQ. catalyzed reaction has been studied extensively 
(Figure 2A), and it appears that the efficacy o f hydrazine 
molecules to inhibit copper amine oxidases is based on their 
ability to form a mimic o f the substrate Schiff base intermediate
with the enzyme.35 In the case o f a natural substrate, the catalytic 
aspartic acid participates in the deamination reaction where its 
role is to abstract a proton from the natural substrate. When a 
hydrazine compound is bound, instead o f a substrate molecule,
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Table 1. Novel VAP-1 Inhibitor Compounds
compd R1 R2 relative configuration ICso VAP-1 (hM)“ ICso MAO C“ M)b selectivity1
2a H H 1R 0.04 ±  0.01 9.90 ±  2.20 250
2b H H IS 0.15 ±  0.01 9.80 ±  1.00 65
5 H C«HS IR*,2S* 50 ± 3 34 ±  3 0.7
8 H (CH2)2CH3 d 120 ±  0.16 11 ± 2 9
11a c h 3 c 6h 5 1R,2S 0.28 ±  0.03 70 ±  12 250
lib c h 3 c 6h s 1S.2S 1.18 ±  0.08 85 ± 9 72
11c c h 3 Q H S 1R,2R 1.06 ±  0.04 99 ±  10 90
lid c h 3 Q H S 1S,2R 0.33 ±  0.02 105 ±  13 320
12e c h 3 (CH2)2CH3 1R*,2S* 0.26 ±  0.04 28 ±  1 110
a ICso data for VAP-1 in fiM, 
experiments.e Calculated IC50
mean dz SEM o f two to four similar experiments. 
(M A O )/IC 5o(VAP-l). d Mixture o f diastereomers.
bIC50 data for MAO 
e Reference 26.
in mean ±  SEM  o f  two to four similar
the enzymatic reaction is halted because the catalytic aspartic acid 
cannot abstract a proton from the secondary amine group.35 The 
reactivity of the hydrazines also makes these molecules excellent 
inhibitors for AOs.
The available 3D crystal structure o f VAP-1 with bound 
inhibitor 2-hydrazinopyridine (PDB code 2C1133) shows the 
general mechanism by which an unsubstituted hydrazine binds to 
VAP-1 (Figure 2B and Figure 2C). The primary amine group of 
the hydrazine binds covalently to the TPQ_cofactor. The secon­
dary amine group o f the hydrazine participates in a hydrogen 
bond, with the C4 oxygen o f the TPQ_ (Figure 2B and 
Figure 2C), with the Asp386 carboxyl group, or with both 
(Figure 2D). This strongly determines the conformation of the 
rest of a molecule.36 On the basis o f the crystal structure o f VAP-1 
with 2-hydrazinopyridine (PDB code 2C1133), the distances and 
angles from the secondary nitrogen atom to the C4 oxygen atom 
of the TPQ_ cofactor and the Asp386 carboxylate group are 
appropriate for hydrogen bonding, suggesting a positively 
charged amine group (Figure 2C). The crystal structure o f 
Escherichia coli amine oxidase, in complex with 2-hydrazinopyr- 
idine (1SPU35), demonstrates another type of binding. In this 
complex structure, the C4 oxygen atom of the TPQ_is situated 
close to the conserved Tyr369, which suggests a shared proton35 
(Figure 2D). The secondary amine o f the 2-hydrazinopyridine 
turns toward the C  6 o f the TPQrather than toward C4, as it does 
in the 2C11 structure,33 showing that hydrogen bonding o f the 
secondary amine group occurs to catalytic Asp383 and in the 
main chain o f Val463. Furthermore, this also suggests a positively 
charged secondary amine group.
The previously published three-dimensional quantitative 
structure—activity relationship model o f VAP-1 hydrazine-de­
rived inhibitors26 predicted that the larger ligands could show 
even higher VAP-1 selectivity over MAO than was earlier 
reported. Here, we have designed, synthesized, and tested the 
in vitro VAP-1 and MAO inhibition potency of eight novel 
hydrazine molecules that substantially enlarge the understanding
of VAP-1 flexibility and its inhibitor binding capability. These 
molecules show high VAP-1 selectivity over MAO. Additionally, 
molecular dynamics (MD) simulations were used to study the 
effect o f bulky inhibitor binding onto the VAP-1 structure. These 
simulations visualize the high reorganization capability of the 
amino adds that line the ligand-binding cavity, providing a new, 
extra space to accommodate the ligands. This space could be 
utilized in the development of new, better, and more selective 
VAP-1 inhibitors. We also show that, compared to the 2-hydra- 
zinopyridine and other nonsubstituted hydrazine molecules, 
substitution on the secondary amine group results in a distinct 
binding mode.
■ RESULTS AND DISCUSSION
Design of Novel Hydrazines. Previously, we reported the 
construction of 3D-QSAR models, based on 47 hydrazine 
molecules and their ICS0 values for VAP-1 and MAO.26 The 
VAP-1 model suggested that introduction o f steric groups to 
position C2 (Table l )  would be beneficial for VAP-1 potency. 
Therefore, we designed a small series of novel hydrazine mole­
cules with varied C2 substituents. The molecules used for model 
building were smaller than the newly designed molecules 
(Table l). Thus, the prediction of novel molecules, using the 
QSAR model, was omitted prior to the synthesis and the in vitro 
testing of molecules.
Synthesis. In the syntheses o f 2a,b, 5, 8, and 11a—d, 
conventional methods for the preparation o f hydrazino 
alcohols37 were applied. Enantiomers o f 2-hydrazino-l-pheny- 
lethanol (2a,b) were prepared by hydrazinolysis o f the corre­
sponding (S)- or (R)-styrene oxide (la ,b ), resulting in a mixture 
o f the regioisomeric products, 2 and 3, in a ratio of about 2:1, 
from which the main components (2a,b) were isolated by 
fractional crystallization of the hydrogen maleate salt. Similarly, 
(l.R*,2S*)-2-hydrazino-l,2-diphenylethanol (5) was obtained
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Scheme l a
4 5
1,2: (1/?): a, (15): b
“ Reagents: (a) H jN N H ^ H20 ,  and EtOH (yield, 52—62%).
Scheme 2a
6 7 8
a Reagents: (a) NaBH4, MeOH (yield, ~100% ); (b) H2N N H 2, H 20 ,  
and EtOH (yield, 53%).
from the ring-opening reaction o f (±)-frans-stilbene oxide (4) 
with hydrazine hydrate (Scheme l) .38
A  nucleophilic substitution reaction of the corresponding bromo- 
substituted alcohol (7) with hydrazine was applied for the synthesis 
o f 2-hydrazino-l-phenylpentanol (8) (Scheme 2) 37,39 Compound 7 
was formed as a diastereomeric mixture in the reduction o f (±)-2- 
bromo-l-phenylpentanone40 (6) with NaBHLj.41 All our efforts to 
separate the diastereomers of 8 have failed.
Isomeric 2-(l-methylhydrazino)-l,2-diphenylethanols 11a— 
d were prepared from enantiomerically pure amino alcohols 9a— 
d,42 44 using a two-step procedure that included N-nitrosation 
and subsequent LiAlH4 reductions o f the N-nitroso intermedi­
ates 10a—d (Scheme 3).
In Vitro Potency. In vitro potencies were determined for the 
synthesized inhibitors 2a,b, 5, 8, and 11a—d (Table l). The in 
vitro potency o f 12 was reported earlier.26 The results indicate 
that the compounds 2a, 11a, and l id  are highly specific 
inhibitors o f human VAP-1 activity. The ICS0 for VAP-1 inhibi­
tion varies from SO to 0.04/¿M (Table l) .  Major differences were 
found in the selectivity of the inhibitors against the total MAO 
potency, with selectivity ranging from nonselective to 320-fold 
selective (Table l).
Binding of 1/?- and 15-2-Hydrazinyl-l-phenylethanol to 
VAP-1. In the crystal structure of VAP-1 with a bound inhibitor, 
2-hydrazinopyridine, Leu469 blocks the ligand-binding cavity.33 
However, as we recently reported, during the MD simulations of 
VAP-1 with inhibitors larger than 2-hydrazinopyridine, Leu469 
rotates and unblocks the ligand-binding cavity, providing to the 
ligands free access from the solvent to the ligand-binding 
pocket.26 This rotated Leu469 conformation was used here as 
the starting structure.
Two stereoisomers of 2-hydrazinyl-l-phenylethanoI ( l R =  2a 
and IS  = 2b; Table l )  are the simplest molecules studied in this 
research. Both stereoisomers were docked to the VAP-1 structural
Scheme 3fl
'¡l ÇH3 l) 9 *
k^ A 2,N H C H 3 g ' V ' % 0 V S h,




9-11: (1R.2S): a, (1S,2S): b, (\R,2R): c, (IS,2R): d
fl Reagents: (a) N aN O * AcOH, H zO (yield, 95—97%); (b) LiAlH4, 
THF (yield, 58-65% ).
model, where Leu469 is rotated, as described above, resulting in a 
similar binding conformation, as seen in the VAP-1-bound 2-hydra- 
zinopyridine (Figure 2C). To understand the binding of 2a and 2b in 
more detail, MD simulations were used to study the complexes 
obtained from the docking. These simulations of VAP-1, with bound 
2a,b, show that the surrounding amino adds Tyr384, Phe389, 
Tyr394, Leu468, and Leu469 form a hydrophobic pocket that nicely 
accommodates the phenyl rings o f 2a and 2b (Figure 3). Both 2a and 
2b can form a tight hydrogen bond network (Figure 3), which 
explains their excellent potency for VAP-1. The orientation of the 
hydroxyl group (LR = 2a and IS  = 2b) represents the greatest 
difference in the ability o f 2a and 2b to bind to VAP-1. The hydroxyl 
group of 2a points away from Tyr384, where it has more space 
(Figure 3A), while the hydroxyl group o f 2b has difficulties 
accommodating itself between the aromatic rings of Tyr384 and 
Phe389 (Figure 3B). This may explain why 2a binds 4 times better to 
VAP-1 than does 2b. The binding o f 2a and 2b induce conforma­
tional changes in two amino add side chains: Met211 and Leu469 
(shown with 2a in Figure 3A). This reveals new free space near C2 of 
2a,b (Figure 3).
Effect of Propyl Substitution at C2. Docking simulations 
indicated that the addition o f a propyl group to C2, compound 8 
(Table l), can utilize the additional space (Figure 4A), revealed 
by the rotation of Met211 and Leu469, during the MD simula­
tion o f VAP-1 with bound 2a and 2b (parts A and B of Figure 3, 
respectively). On the basis o f the binding o f 2a and 2b (parts A 
and B of Figure 3), the 1R,2S enantiomer of 8 is optimal for 
binding to VAP-1 because (a) the hydroxyl group can freely 
interact with the Asp386 and (b) the 2S-propyl can accommo­
date itself into the space formed by the rotation of Met211 and 
Leu469, during the MD simulation o f VAP-1 with bound 2a,b 
(Figure 4A). Although compound 8 seems to fit into the VAP-1 
ligand-binding site, its inhibitory activity is clearly worse than the 
inhibitory activity of 2a and 2b (Table l).
As previously reported, the methylation of the secondary 
amine at the hydrazine moiety (N-methylation) can lower the 
potency of ligands.26 However, the N-methylation of 8 increases 
the potency because the IC50 value o f N-methylated 12 is 0.26 
ftM. while the ICS0 value o f nonmethylated 8 is 1.20 fiM. 
(Table l). In order to study the binding o f the N-methylated 
compound 12 (lR,2S), it was docked into the VAP-1 conforma­
tion obtained from the MD simulations with 2a. As expected, the 
N-methylated compound 12 yielded a distinct conformation 
than did the nonmethylated compound 8 (Figure 4). The N- 
methyl group of 12 points toward the main chain of Leu469, 
whereas in compound 8, the hydrogen o f the same nitrogen atom 
is hydrogen-bonded with Asp386 and the hydroxyl group of 
TPQ_ (Figure 4). The conformation o f 8 is further stabilized by
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Figure 3. Binding of 2a,b to VAP-1 (parallel stereoview). (A) In the course o f MD simulation the side chains o f M et2Il and Leu469 change their 
conformation (black sticks) but the rest o f the side chains remain dose to the starting conformations (gray sticks). TP Q —2a is shown in ball-and-stick. 
The phenyl ring of 2a is surrounded by hydrophobic Leu468 and Leu469 and aromatic Tyr384, Phe389, and Tyr394 (surface rendering). Multiple 
hydrogen bonds are present: Asp386 forms hydrogen bonds (black dashed lines) ( l )  to TPQhydroxyl group, (2) to second nitrogen of the hydrazine 
functionality, and (3) to the hydroxyl group o f  the 2a. The second nitrogen of 2a forms a hydrogen bond with TPQhydroxyl group. (B) The surface 
rendering o f the amino adds closest to 2b reveals space near C2 o f 2b. The hydrogen bond network (black dashed lines) between T P Q  2b, and Asp386 
is as tight as in the case of 2a. The movement o f M et211 is not as prominent as in die case of 2a.
the hydrogen bond between the hydroxyl group o f 8 and Asp386 
(Figure 4A). Compound 12 forms only two hydrogen bonds: ( l)  
Asp386, the hydroxyl group of T P Q  and (2) Asp386, the 
hydroxyl group of 12 (Figure 4B). Accordingly, the conforma­
tion o f 8 is more strongly determined by hydrogen bonding, and 
these interactions force 8 into a bended conformation. This 
bended conformation restricts the C2 propyl substituent o f 8 
from taking advantage of all the extra space created by the 
rotation of the Met211 side chain. In compound 12, whose 
conformation is not strictly determined by hydrogen bonding, 
the propyl substituent can extend deeper into the extra space 
(Figure 4). This can be seen as the difference in IC50 values 
between 8 and 12, which are 1.20 and 0.26 /lM , respectively 
(Table l).
Effect of Phenyl Substitution at C2. The MD simulations of 
VAP-1 with bound 2a and 2b (Figure 3) and the dockings o f 8 
and 12 (Figure 4) into VAP-1 clearly show that in compounds 8 
and 12, it is possible to add an even larger substituent than propyl 
to the C2-position. In the compound series 11, the C2 sub­
stituent is phenyl (R2 in Table l )  while the C l  substituent is 
methyl (R1 in Table l), which is the same as in compound 12. 
The docking o f the l ia  (IR, 2S) into VAP-1 conformation, 
obtained in the MD simulation o f VAP-1 with bound 2a,b, shows 
that the phenyl might fit into the VAP-1 ligand-binding site. 
However, it is difficult to use static protein conformation to
predict the binding o f other enantiomers o f 11, Le., lib , 11c, and 
lid . Therefore, to understand the exact binding modes of the 
enantiomers, we docked all four enantiomers ( lla —d) into a 
VAP-1 crystal structure33 where the Leu469 side chain was rotated, 
as described above, and then the complexes were simulated 
with MD.
The IC50 data o f VAP-1 inhibition o f l la —d are intriguing. 
Although these molecules differ significantly in their stereo 
configuration, and thus also in their three-dimensional structure, 
their VAP-1 inhibition potencies show some similarities ( l la  is 
only 4 times more potent than l ib )  (Table l). The MD 
simulations performed for l l a —d bound to VAP-1 indicate 
two different hydrogen bonding partners for the C l hydroxyl 
group, which ( l)  in l l a  and l ib  form a hydrogen bond to the 
T P Q  (parts A and B o f Figure 5, respectively) while (2) in 11c 
(Figure 5C) and l id  (Figure 5D) form a hydrogen bond to the 
Asp386. Regardless o f whether the hydroxyl group of the ligand is 
hydrogen-bonded with the T P Q  or the Asp386, one of the 
phenyl rings is turned into the hydrophobic pocket formed by 
Tyr384, Phe389, Tyr394, Leu468, and Leu469 (Figure 5) and 
the N-methyl is pointed toward Ala370. In the conformation in 
which an intramolecular hydrogen bond with T P Q  exists, the 
phenyl ring at carbon 2 points toward the hydrophobic pocket 
( l la  and lib , parts A  and B o f Figure 5). However, with the 11c 
and l id  enantiomers, whose conformation is driven by the
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Figure 4. Binding modes o f (A) 8 and (B ) 12 based on docking simulations to VAP-1 conformation obtained from MD simulations (parallel 
stereoview). (A) The bound 8 and TPQ_are shown in ball-and-sticL A groove formed between Ser496, Met211, and Leu469 can accommodate the C2 
substituent A  similar hydrogen bond network is formed as in 2a. (B) The binding o f  12 is distinct to 8 because o f the methylation o f the second nitrogen 
atom. Asp386 can form hydrogen bonds to ( l )  hydroxyl group of 12 and (2) hydroxyl group o f TPQ. The phenyl ring of 12 is buried inside the 
hydrophobic pocket, similar to that in 8. The propyl substituent extends toward M et211. The N-methyl substituent points toward Leu469 main chain. 
The hydroxyl group o f 12 is closer to the hydroxyl group o f TPQ, than the hydroxyl group o f 8 .
hydrogen bonding with the Asp386 (parts C and D of Figure 5), 
the phenyl ring attached to carbon 1 points toward the hydro- 
phobic pocket The phenyl ring that is not buried inside the 
hydrophobic pocket forms a JZ—JZ interaction either with Tyr372 
or with Tyr384 (Figure 5).
The conformational changes observed in the MD simulations of 
VAP-1 with bound inhibitors are predominantly rotational changes 
in the side chains of the amino adds. The most substantial changes in 
the conformations of the amino adds in the ligand-binding pocket 
are related to Met211, Leu469, and TPQ, conformations. Interest­
ingly, the conformation of Leu469 seems to be dependent upon the 
C2 configuration of the ligand. Here, with 1 lc  and 1 Id, the Leu469 
returns to the conformation seen in the crystal structure (le., to block 
the ligand-binding cavity33). However, with the 11a and l ib  
diastereomers, Leu469 remains in the conformation, where access 
to the ligand-binding cavity is free. The conformation of Met211 is 
not dependent upon configurations o f C l and C2. In compounds 
11a—d, Met211 turns away from the bound ligand revealing extra 
space (Figure 5). This is similar to the conformation of Met211 in 
compounds 2a and 2b (Figure 3). The conformation of TPQ, also 
alters on the course o f MD simulation, depending upon the C2 
configuration of the ligand. With 11c and l id ,  the TPQ, moves to 
resemble the inactive conformation34 more than the active 
conformation.33 This change in TPQ,conformation does not affect 
the hydrogen-bonding network.
It was expected that the removal of the N-methyl from 11 
would reduce inhibitory activity, just as it did in the molecule pair 
8 and 12. Indeed, the ICS0 for 5 is 50/¿M, whereas those o f 1 l a — 
d vary between 0.28 and 1.18 [¿M (Table l). Accordingly, 
N-methylation increases the VAP-1 potency if, simultaneously, 
C2 has a large substituent. This is interesting because without the 
C2-substitution the N-methylation has an opposite effect.26
VAP-1 over MAO Selectivity. A1 the compounds evaluated in 
this study are weak MAO inhibitors showing only a 10-fold 
variation in MAO inhibition: 2a (9.90 /iM.), 2b (9.80 [¿M), 8 (11 
/<M), 11a (7 0 /¿M), l i b  (85 fiM), l i e  (99/¿M), l i d  (105/¿M), 
12 (28 /UM), and 5 (34 /¿M). Thus, in general, N-methylated 
compounds with a phenyl substituent at the R2-position ( l l a — 
d) are slightly worse inhibitors o f MAO than those that do not 
have this type o f substituent (2, 5, 8, and 12) (Table l ) . In 
contrast, the N-methylation for VAP-1 inhibition has an opposite 
effect; in this set o f compounds, the N-methylation significantly 
increases the selectivity toward VAP-1 over MAOs (Table l).
The size o f the molecule has a negative effect on the MAO 
binding (Figure 6) because the ligand-binding pocket in the MAO 
is smaller than it is in the VAP-1. On the basis o f the crystal 
structure o f human MAO B in complex with phenylethylhydra- 
zine, i.e., phenelzine,4S it can be postulated that both nitrogens of 
hydrazine moiety are cleaved off during the course o f the reaction 
and the remaining part of the ligand forms a covalent bond with
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Figure 5. Binding conformations o f 11a—d to VAP-1 based on MD simulations (parallel stereoview). Starting structure of VAP-1 MD simulation is 
visualized in gray and final structure in green. TPQ.—ligand complexes and surrounding amino acids are represented in ball-and-sticks and sticks, 
respectively. Hydrogen bonds in MD starting structure are drawn with dotted black line, and those in M D final structure are drawn with dotted orange 
line. All main chain atoms are omitted. (A) The binding o f  1 la  to VAP-1. In the MD simulation starting structure the ligand forms hydrogen bond with 
Asp386. In the final structure the ligand OH group has moved markedly. This change recruits Tyr372 and Tyr384 to form hydrogen bonds that were 
initially absent, resembling the final structure o f the 1 lb . (B ) Binding o f  1 lb  to YAP-1. The ligand has formed a hydrogen bond with the TP Q.OH group. 
The surrounding tyrosines Tyr372 and Tyr384 also form hydrogen bonds to the ligand and TPQ. Tyr372 changes its conformation during the 
simulation, and in the final structure it is close enough to be hydrogen-bonded to Tyr384. The overall conformation o f the ligand does not change 
markedly. (C ) Binding o f 1 lc  to VAP-1. Ligand OH group forms a hydrogen bond with Asp386. Surrounding aromatic amino acids (Tyr372, Tyr384, 
and Phe389) undergo conformational changes during simulation as the ligand moves. TPQjmoves toward the protein core. (D ) Binding of 1 Id  to VAP- 
I. The ligand is hydrogen-bonded to the Asp386 throughout the simulation. The TPQ.—ligand complex moves slightly toward the protein core. A 
hydrogen bond between Tyr372 and TPQ .O H  group can be detected.
Figure 6. Binding o f S and 8 into MAO B ligand binding site. The ligand binding pocket of MAO is small and narrow (represented as green surface). 
The ligands, 5 and 8, are covalently docked to the nitrogen o f cofactor FAD and are represented as ball-and-sticks. The reaction product of 8 (A) fits 
slightly better into the ligand binding pocket o f MAO than that o f 5 (B), thus explaining their difference in inhibitor potency to MAO. The surrounding 
tyrosines, Tyr60, Tyr398, and Tyr435, of the ligand binding pocket are shown as transparent ball-and-sticks.
the nitrogen atom at the central ring o f the FAD. The docking 
simulations of the probable covalent reaction product o f 8 
(l-phenyl-2-propanylethanol, Figure 6A) and 5 ( 1,2-dipheny- 
lethanol, Figure 6B) to MAO B indicate that the MAO ligand­
binding site is too small to properly accommodate these 
compounds. Furthermore, the MAO ligand-binding site is too 
small to accommodate compounds I l a —d (data not shown). 
However, it is notable that the propyl group of 8, at R2-position, 
fits slightly better into the MAO ligand-binding site (Figure 6A), 
possibly explaining the small difference in their potency 
(Table l). Additionally, the docking o f 8 into the MAO ligand­
binding site is easier because o f the flexibility o f the propyl group 
in contrast to the phenyl group in 5.
The negative effect o f N-methylation on MAO binding 
may be explained by the lowered reactivity o f the N-methylated
molecules compared to the reactivity of the nonsubst- 
ituted molecules. Even though molecules 8 and 12 yield 
the same reaction product in MAO, N-methylated compound 
12 has only half o f the inhibition activity for MAO than does 
compound 8, which is not N-methylated (Table l). Similarly, 
non-N-methylated compound 5 has twice the potency to 
MAO than do the N-methylated compounds l i a —d 
(Table l).
■ CONCLUSIONS
This study has explored the flexibility o f the VAP-1 ligand­
binding site and developed several novel VAP-1 selective in­
hibitors over MAO. The MD simulations show that the static 
crystal structures o f VAP-1 provide only a limited view into
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ligand-binding capability. The VAP-1 ligand-binding site can 
accommodate bulkier inhibitors than can MAO. Additionally, the 
N-methylation of large hydrazines increases the potency of VAP- 
1 while the inhibition o f MAO is simultaneously reduced, thus 
leading to VAP-1 selectivity. Altogether, these findings open up 
new avenues into the discovery o f novel and selective inhibitors 
to treat diseases related to VAP-1.
■ MATERIALS AND METHODS
Materials. Cell culture reagents were supplied by Gibco. Other 
chemicals were o f analytical or reagent grade and were purchased from 
commercial suppliers.
Synthesis of the Novel Hydrazine-like Molecules. General 
Methods. Melting points were measured on a Kofler hot-plate micro­
scope apparatus and are uncorrected. For routine thin-layer chromatog­
raphy (TLC), silica gel 60 F254 plates (Merck, Germany) were used. 
Elemental analyses were performed with a Perkin-Elmer 2400 CHNS 
elemental analyzer. *H  N M R  spectra were recorded in CDC13, in 
DMSO-d6, or in D 20  solutions on a Bruker DRX 400 spectrometer. 
These spectra indicated the >95% purities of the prepared compounds. 
Chemical shifts are given in 6  (ppm ) relative to TM S (DMSO-d6) or to 
TSP (D20 )  as internal standards.
General Procedure for the Preparation ofHydrazino Alcohols 2a,b . 
To a stirred solution o f  hydrazine hydrate (5.01 g, 0.10 mol) in EtOH 
(10 mL) a solution o f (R )- or (S)-styrene oxide ( la  or lb , 1.20 g, 10 
mmol) in EtOH (5 m L) was added dropwise. After addition was 
complete, the mixture was kept at 60 °C  for 10 min. The solvent was 
evaporated off, and the oily residue was dissolved in EtOH and treated 
with an equivalent amount o f maleic acid. The separated crystals o f the 
corresponding maleates (2a,b) were filtered off and recrystallized.
(R) -2-Hydrazino-l-phenylethanol Hydrogen Maleate (2 a  Hydro­
gen Maleate). Beige crystalline solid; yield 1.45 g (54%); mp 98—
103 °C  (EtOH—Et20 ) ;  [ a ] D - 4 4  (MeOH, c 0.50). *H NM R (D20 )  d 
3.38 (m, 2H, / =  7.9 Hz, N CH 2), 5.07 (dd, 1H, /  =  7.1, 5.7 Hz, OCH), 
6.30 (s, 2H, C H =C H ), 7 .3 8 -7 .5 0  (m, 5H, Q H 5). Anal. Calcd for 
C 12H 16N20 5: C, 53.73; H, 6.01; N, 10.44. Found: C, 53.51; H, 5.93; 
N, 10.28.
(S) -2-Hydrazino-l-phenylethanol Hydrogen Maleate (2b  Hydro­
gen Maleate). Beige crystalline solid; yield 1.40 g (52%); mp 99—
104 °C  (EtOH—EtzO ); [ a ] D + 4 3  (M eOH, c 0.50). The *H NMR 
(D 20 )  spectrum was identical to that o f the (R)-enantiomer (2a 
hydrogen maleate). Anal. Calcd for C I2H i6N 20 5: C, 53.73; H, 6.01;
N, 10.44. Found: C, 53.64; H , 5.85; N, 10.38.
(1 R*,2R*)-2-Hydrazino- 1,2-diphenylethanol Hydrogen Maleate (5 
Hydrogen Maleate). To a solution o f  (±)-ira«s-stilbene oxide (4,1.57 g,
8 mmol) in EtOH (10 m L) hydrazine hydrate (5.01 g, 100 mmol) was 
added. The mixture was heated under reflux for 12 h. The solvent and 
the unreacted hydrazine hydrate were evaporated off, and evaporation 
was repeated twice after addition o f  toluene (10 mL). The oily residue 
was treated with an equivalent amount o f maleic acid in a mixture of 
EtOH and Et20  to give crystalline maleate salt which was filtered off and 
recrystallized. White crystalline substance; yield 1.71 g (62%); mp 159— 
160 °C  (E t0 H -E t2O ). JH  N M R  (D zO ) 6  (ppm ): 4.41 (d, l H , / =  6.5 
Hz, NCH), 5.10 (d, 1H, /  =  6.5 Hz, O C H ), 6.30 (s, 2H, CHCOOH) 
7.28-7.49 (m, 10H, 2 x  Q H 5) . Anal. Calcd for C ^ H ^ N ^ :  C, 62.78;
H, 5.85; N, 8.13. Found: C, 62.50; H, 5.67; N, 7.96.
2-Hydrazlno-l-phenylpentanol Hydrogen Fumarate (8 Hydrogen 
Fumarate). To a stirred and ice-cooled solution of (±)-2-bromo-l- 
phenyl-l-pentanone (6, 2.41 g, 10 mm ol) in methanol (30 mL) N aB R , 
(0.38 g, 10 mmol) was added in small portions, and the resulting mixture 
was stirred for 2 h with ice—water bath. The mixture was then acidified 
with 10% HC1 and evaporated in vacuo. The residue was partitionated 
between water (30 mL) and Et20  (25 m L), and the aqueous phase was
extracted with Et20  (2 x  25 mL). The combined organic phases were 
dried (N a2S 0 4)  and evaporated to give compound 7  as an oily product 
which was used in the next step without further purification. Yield: 2.42 g 
( ~ 100% ).
T o  a solution o f compound 7 (2.42 g, 10 mmol) in ethanol (30 mL) 
hydrazine hydrate (2.50 g, 50 mmol) was added, and the mixture was 
heated under reflux for 6 h. The solvent and the unreacted hydrazine 
hydrate were evaporated off, and evaporation was repeated twice after 
addition o f  toluene (10 mL). The oily residue was treated with an 
equivalent amount o f fumaric acid in a mixture of EtOH and Et20  to give 
crystalline fumarate salt which was filtered off and recrystallized. Beige 
crystalline substance; yield 1.64 g (53%); mp 170 °C  (decomposition) 
(EtO H —EtzO ). ‘H  NM R (DMSO-d6) 6  (ppm): 0.68 (t, 3 H ,/=  7.0 Hz, 
CH3), 0 .94-1 .36 (m, 4H, 2 x  CH2), 2.80-2.91 (m, 1H, N C H ), 4.53 
(d, l H , / =  8.2 Hz, OCH ), 6.51 (s, 2H, CHCOOH), 7 .16-7 .42  (m, 5H, 
Q H 5). Anal. Calcd for C ^ H ^ O s :  C, 58.05; H, 7.15; N , 9.03. Found: 
C, 57.75; H, 6.94; N, 8.89.
General Procedure for the Preparation o f N-Nitrosoamino Alcohols 
1 0 a —d. A solution o f N aN 0 2 (1.38 g, 20 mmol) in H20  (10 m L) was 
added dropwise to a suspension o f the corresponding isomer of 
2-methylamino-l,2-diphenyl-l-ethanol (7a—d, 2.27 g, 10 mmol) (10 
mmol) in H 20  (25 m L) with vigorous stirring on an ice-cold bath, and 
then AcOH (0.90 g, 15 mmol) was added dropwise. The mixture was 
stirred at room temperature for 8 h, then was extracted with EtOAc (4  x  
30 mL). The combined organic phases were dried (N a2S 0 4) and 
evaporated under reduced pressure to give the N-nitroso derivative as 
a crystalline product, which was filtered and washed with n-hexane. 
Yield: 2.44—2.49 g (95—97%). The crude product was used in the next 
step without further purification.
General Procedure for the Preparation of Hydrazino Alcohols 11a-  
d. A  solution o f the corresponding isomer of 2-methylamino-N-nitroso- 
1,2-diphenyl-1-ethanol (10a—d, 1.54 g, 6 mmol) in THF (12 m L) was 
added dropwise to a strirred and ice-cooled suspension o f  L 1AIH4 (0.46 
g, 12 mmol) in TH F (25 mL), and the mixture was stirred at ambient 
temperature for 3 h. The excess o f LiAlH4 was decomposed with a 
mixture o f H20  (l.O mL) and TH F (20 mL). The resulting precipitate 
was filtered off and washed with EtOAc (3 x  25 mL). The combined 
filtrate and washings were dried (Na2S 0 4) and evaporated under 
reduced pressure. The oily residue was treated with an equivalent 
amount of fumaric add ( l lb ,c )  or (S,S)-tartaric add ( l l a ,d )  in a 
mixture o f EtOH and Et20  to give crystalline salts which was filtered off 
and recrystallized. The salt formations o f 1 lb  and 1 lc  with fumaric add 
occurred in 1:1 ratio, while tartrates of 11a and l i d  could be character­
ized by the 2:1 ratios o f the base and add components.
( lR,2S)-2-( 1-Methylhydrazino)- 1,2-diphenylethanol (S,S)-Tartrate 
[11a (S,S)-Tartrate). White crystalline substance; yield 1.10 g (58%); 
mp 1 4 1-143  °C  (EtO H —Et20 ) ;  [ a ] D - 8 5  (MeOH, c 0.57). *H NM R 
(D 20 )  6  (ppm ): 2.95 (s, 3H, NCH3), 4.35 (s, 1H, CHO HCO OH), 4.45 
(d, 1 H J  =  4.8 Hz, N C H ), 5.67 (d, 1 H J = 4.8 Hz, OCH), 7 .18-7 .46  (m, 
10H, 2 X C^Hs). Anal. Calcd for C i7H21N20 4: C, 64.34; H, 6.67; N, 
8.83. Found: C, 64.28; H, 6.31; N, 8.99.
( lS2S)-2-( 1-Methylhydrazino)- 1,2-diphenylethanol Hydrogen Fu­
marate (11b Hydrogen Fumarate). White crystalline substance; yield
1.33 g (62%); mp 1 5 3-154  °C  (EtOH—Et20 ) ;  [d ]D - 4 4  (MeOH, c
0.40). *H  N M R (D 20 )  6 (ppm): 2.83 (s, 3H, NCH3), 4.62 (d, 1H,
J  =  10.3 Hz, N C H ), 5.43 (d, 1H, /  =  10.3 Hz, OCH), 6.60 (s, 2H, 
C H CO O H ), 7 .10-7 .46  (m, 10H, 2  x  Q H j) . Anal. Calcd for 
C j^ ^ N z O j :  C, 63.67; H, 6.19; N , 7.82. Found: C, 63.68; H, 5.93;
N, 7.66.
(1R,2R)-2-(1-Methylhydrazino)-1,2-diphenylethanol Hydrogen Fu­
marate (11c Hydrogen Fumarate). White crystalline substance; yield 
1.40 g  (65%); mp 150-152  °C  (EtOH—Et20 ) ;  [d ]D + 4 1  (MeOH, c
O. 40). The *H N M R (D zO ) spectrum was identical to that o f the (1S,2S)
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enantiomer ( l i b  hydrogen fumarate). Anal. Calcd for Q 9H 22N 2O5: C, 
63.67; H, 6.19; N , 7.82. Found: C, 63.45; H, 6.08; N, 7.71.
( 1S,2R)-2-( 1-Methylhydrazino)-1 ¿-diphenylethanol (S,S)-Tartrate 
[ l i d  (S,S)-Tartrate]. White crystalline substance; yield 1.24 g (65%); 
mp 167-170  °C  (EtOH—EtjO ); [ a ] D + 7 8  (MeOH, c 0.55). ‘H  NM R 
(D20 )  6 (ppm ): 2.94 (s, 3H, NCH3),4.35 (s, 1H, CHO H CO O H ), 4.44 
(d, 1H ,/= 4 .9 H z , N C H ),5.66 (d, lH ,/= 4 .9 H z , OCH ), 7 .18-7 .46  (m, 
10H, 2 x  C$HS). Anal. Calcd for C 17H21N2O4: C, 64.34; H, 6.67; N, 
8.83. Found: C, 64.07; H, 6.48; N, 8.51.
Expression of Recombinant VAP-1. Recombinant VAP-1 pro­
tein was obtained from Chinese hamster ovary (C H O ) cells stably 
transfected with a full-length human VAP-1 cD N A  Recombinant 
human VAP-1 SSAO expressed in CHO cells was used as a source of 
VAP-1 for activity measurements. Native CHO cells have negligible 
VAP-1 activity. These cells and their culture have previously been 
described.46 A  cell lysate was prepared by suspending approximately 
3.6 x  108 cells in 25 m Loflysis buffer (150 m M NaCl, lOm M Trisbase, 
pH 7.2,1.5 mM MgCl2, 1% NP40) and incubating at 4  °C  overnight on a 
rotating table. The lysate was clarified by centrifugation at 18000gfor 5 
min at room temperature and the supernatant used directly in the assay.
Mitochondrial MAO Extract. Rat total monoamine oxidase 
enzyme (MAO, mixture o f MAO A and MAO B) was prepared from 
rat liver tissues by rinsing the liver sample several times in KC1—EDTA 
solution to remove all blood. Then the liver sample was homogenized in 
ice-cold potassium phosphate buffer (0.1 M, pH  7.4) with an Ultra- 
Turax homogenizer (setting 11 000 rpm, 4 x 1 0  s). After centrifugation 
at 500g for 10 min at 4  °C  the supernatant was carefully withdrawn and 
was centrifuged at 12300g for 15 min at 4  °C . The supernatant was 
discharged, and sedimented mitochondria were resuspended in fresh 
phosphate buffer and centrifuged as previously. The mitochondria were 
suspended in phosphate buffer and homogenized with an Ultra-Turax 
homogenizer (setting 11000 rpm, 2 x  10 s). Mitochondrial preparate 
was aliquoted and stored at —70 °C .
In Vitro Inhibition Activity. VAP-1 activity was measured as 
described previously26 using the coupled colorimetric method essen­
tially as described for monoamine oxidase and related enzymes.47 In 
short, the assay was performed in 96-well microtiter plates as follows. 
The inhibitor concentrations used varied between 1 nM and 50 f.iM. The 
assay was performed in a final volume o f 200 /¿L  consisting o f 0.2 M 
potassium phosphate buffer (pH 7.6) and freshly made chromogenic 
solution containing 1 mM 2,+dichIorophenol, 500 fiM. +aminoanti- 
pyrine, and 4  U /m L horseradish peroxidase and an amount o f CHO cell 
lysate containing VAP-1 SSAO that caused a change o f O.6A490 per h. 
The plates were incubated for 30 min at 37 °C . T o  initiate the enzymatic 
reaction, 1 mM benzylamine was added and the plate incubated for 1 h at 
37 °C . The increase in absorbance, reflecting VAP-1 SSAO activity, was 
measured at 490 nm by using Wallac Victor II multilabel counter. The 
IC50 values for the inhibitors were calculated using GraphPad Prism 
software. Since MAO A  and MAO B have similar amino acids at the 
proposed inhibitor binding site (Figure 6), the ICS0 values for MAOs 
were measured only for the mixture o f MAO A  and MAO B. Total MAO 
activity was measured in a similar way as for VAP-1 SSAO except that 
2,+dichlorophenol was replaced by 1 mM vanillic add, and benzylamine 
was replaced by tyramine in 0.5 mM final concentration.
Docking of Ligands to VAP-1 and MAO B Ligand Binding 
Pockets. The crystal structure o f VAP-1 in complex with 
2-hydrazinopyridine33 was retrieved from the Protein Data Bank.48 
The conformation o f the side chain o f Leu469 was changed to resemble 
that obtained from MD simulations26 using amino acid side chain 
rotamer library49 incorporated into BODIL modeling environment.50 
In addition, the water molecules and the atoms o f bound inhibitor 
molecule 2-hydrazinopyridine (C l, C2, C3, C4, C5, and N3 in the 
crystal structure) were removed. Hydrogen atoms were added using 
SYBYL51 Ligands were sketched in SYBYL and energy-minimized by
ARTICLE
using MMFF94s force field with M M FF94 charges and conjugate 
gradient method until the energy gradient was less than 0.05 kcal/ 
moL Bioactive conformations for studied ligands were predicted with 
GOLD 3.1.1. The ligand binding pocket was defined using the C^H 
from Leu468 as a central atom with radius o f 20 A. The ligands were 
docked covalently to TPQ. Each ligand was docked 10 times; however, 
the docking simulation was allowed to terminate in cases where the root- 
mean-squared deviations o f the three best conformations were within 
1.5 A  Compounds 5 ,8, and 12 were docked on the final conformation of 
the MD simulation of VAP-1 with 2a instead o f the modified crystal 
structure o f VAP-1 described above. Docking of ligands into crystal 
structures o f MAO AS2 and MAO B45 was performed with GOLD 3.1.1 
similarly as docking to VAP-1. Molecules were docked covalently to the 
nitrogen atom of cofactor FAD.
Starting Structures for Molecular Dynamics Simulations.
The starting structure of VAP-1 with an active conformation of cofactor 
T P Q 12 was retrieved from the Protein Data Bank.48 Leu469 side chain 
was turned as described earlier.26 As all studied inhibitor molecules bind 
covalently to TPQ* the TPQ.—ligand systems were parametrized as 
follows. TPQ— ligand complexes were built with SYBYL 7.351 and 
optimized with Gaussian 0353 at the H F /6 -3 1 + G * leveL The electro­
static potentials o f the ligands were calculated with Gaussian 03 (H F /6- 
3 1 + G *) for the optimized TPQ.—ligand complexes, and the RESP 
methodology54 was used to create atom-centered point charges from the 
electrostatic potentials. Finally, hydrogens, neutralizing counterions 
(N a+  ions), and TEP3P water molecules extending 13 Á  around the 
protein complex (rectangular box) were added with LEAP.55
Molecular Dynamics Simulations. All energy minimizations and 
molecular dynamics simulations were performed with NAMD 2.6s6 using 
fiD3 force field parameters57 for the protein and gafi99 parameters58 for the 
ligands (T P Q +  compounds 2a,b and 11a—d). The whole MD simulation 
procedure comprised two minimization runs (the minimization of water 
molecules, counterions, and amino add side chains, followed by the 
minimization for the whole complex) and two MD simulations. The first 
MD simulation (360 ps) where the Get atoms were restrained was 
performed at constant pressure. The 2.4 ns production simulation was 
performed without constraints. The simulated complexes were held at 
constant temperature (300 K ) with Langevin dynamics for all non-hydrogen 
atoms, using a Langevin damping coeffident o f 5 ps - I . A constant pressure 
of 1 atm was upheld by a Nősé—Hoover—Langevin piston59 with an 
oscillation time scale o f 200 fc and a damping time scale of 100 6 . An 
integration time step of 2 fs was used under a multiple time stepping 
scheme.60 The bonded and short-range interactions were calculated every 
third step. A  cutoff value of 12 Á  was used for the van der Waals and short- 
range van der Waals forces to smoothen the cutoff. The simulations were 
conducted under the periodic boundary conditions with the full system, and 
the long-range electrostatics were counted with the partide-mesh Ewald 
method.61 The bonds involving hydrogen atoms were restrained by the 
SHAKE algorithm62 Snapshot structures from the MD trajectories were 
visually inspected to understand the potendes and effects of inhibitors to the 
structure of the catalytic site.
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